Literature DB >> 25215266

Intratympanic Therapies for Menière's disease.

Matthew W Miller1, Yuri Agrawal2.   

Abstract

There are multiple treatment options to consider when managing patients with Menière's disease. When conservative measures fail to control symptoms of Menière's disease, escalation of interventions may be required. Targeted drug delivery to the round window with intratympanic injections allows for local application of high concentrations of medications, largely avoiding systemic side effects. Intratympanic steroids have been shown to be effective at controlling vertigo symptoms, with less robust control rates than those seen with the use of intratympanic gentamicin. Dosing strategies have been modified over time to limit the potential for intratympanic gentamicin-induced ototoxicity. The introduction of intratympanic steroids coupled to a polymer designed for sustained round window drug application, may potentially afford improved duration of symptom control. This review evaluates the recent literature over the last year involving intratympanic therapies for Meniere's disease.

Entities:  

Keywords:  Meniere’s disease; dexamethasone; endolymphatic sac surgery; gentamicin; intratympanic; methylprednisolone; steroid; therapy; transtympanic; treatment

Year:  2014        PMID: 25215266      PMCID: PMC4157672          DOI: 10.1007/s40136-014-0055-8

Source DB:  PubMed          Journal:  Curr Otorhinolaryngol Rep


  26 in total

1.  Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis.

Authors:  Stanley H Chia; Anthony C Gamst; John P Anderson; Jeffrey P Harris
Journal:  Otol Neurotol       Date:  2004-07       Impact factor: 2.311

2.  Treatment of vestibular disorders.

Authors:  A Itoh; E Sakata
Journal:  Acta Otolaryngol Suppl       Date:  1991

Review 3.  Issues, indications, and controversies regarding intratympanic steroid perfusion.

Authors:  Mohamed Hamid; Dennis Trune
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 2.064

4.  Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial.

Authors:  Marco Antonio Garduño-Anaya; Heloísa Couthino De Toledo; Ramón Hinojosa-González; Carlo Pane-Pianese; Luis Camilo Ríos-Castañeda
Journal:  Otolaryngol Head Neck Surg       Date:  2005-08       Impact factor: 3.497

5.  Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Meniere's disease.

Authors:  L Sennaroglu; G Sennaroglu; B Gursel; F M Dini
Journal:  Otolaryngol Head Neck Surg       Date:  2001-11       Impact factor: 3.497

Review 6.  Outcomes of intratympanic gentamicin injection to treat Ménière's disease.

Authors:  Leh-Kiong Huon; Te-Yung Fang; Pa-Chun Wang
Journal:  Otol Neurotol       Date:  2012-07       Impact factor: 2.311

7.  Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H/HeJ mice.

Authors:  Dennis R Trune; J Beth Kempton; Andrew R Harrison; John L Wobig
Journal:  Hear Res       Date:  2006-11-13       Impact factor: 3.208

8.  The effect of intratympanic methylprednisolone and gentamicin injection on Ménière's disease.

Authors:  Nathalie Gabra; Issam Saliba
Journal:  Otolaryngol Head Neck Surg       Date:  2013-01-11       Impact factor: 3.497

9.  Intratympanic gentamicin for Meniere's disease: short- and long-term follow-up of two regimens of treatment.

Authors:  Augusto P Casani; Niccolò Cerchiai; Elena Navari; Iacopo Dallan; Paolo Piaggi; Stefano Sellari-Franceschini
Journal:  Otolaryngol Head Neck Surg       Date:  2014-01-29       Impact factor: 3.497

10.  Control of vertigo after intratympanic corticoid therapy for unilateral Ménière's disease: a comparison of weekly versus daily fixed protocols.

Authors:  Eduardo Martin Sanz; Christiane Zschaeck; Zschaeck Luzardo Christiane; Manuel Gonzalez; Gonzalez Juliao Manuel; Teresa Mato; Mato Patino Teresa; Laura Rodrigañez; Rodrigañez Riesco Laura; Rafael Barona; Rafael Barona De Guzmán; Ricardo Sanz; Sanz Fernandez Ricardo
Journal:  Otol Neurotol       Date:  2013-10       Impact factor: 2.311

View more
  7 in total

1.  Comparison of Enhancement of the Vestibular Perilymph between Variable and Constant Flip Angle-Delayed 3D-FLAIR Sequences in Menière Disease.

Authors:  S Nahmani; A Vaussy; C Hautefort; J-P Guichard; A Guillonet; E Houdart; A Attyé; M Eliezer
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-19       Impact factor: 3.825

2.  In vivo imaging of saccular hydrops in humans reflects sensorineural hearing loss rather than Meniere's disease symptoms.

Authors:  Arnaud Attyé; Michael Eliezer; Maud Medici; Irène Tropres; Georges Dumas; Alexandre Krainik; Sébastien Schmerber
Journal:  Eur Radiol       Date:  2018-03-21       Impact factor: 5.315

3.  Effects of an Intratympanic Injection of Dexamethasone Combined with Gentamicin on the Expression Level of Serum P0 Protein Antibodies in Patients with Meniere's Disease.

Authors:  Yang Geng; Wenping Cao; Huijuan Xu; Fengfang Wu; Tao Feng
Journal:  Clinics (Sao Paulo)       Date:  2020-11-30       Impact factor: 2.365

4.  Radiologic anatomy of the round window relevant to cochlear implantation and inner ear drug delivery.

Authors:  Peter L Nguy; Sheela Saidha; Ann Jay; H Jeffrey Kim; Michael Hoa
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-06-20

5.  Methylprednisolone versus Dexamethasone for Control of Vertigo in Patients with Definite Meniere's disease.

Authors:  Elham Masoumi; Sasan Dabiri; Mohammad Taghi Khorsandi Ashtiani; Reza Erfanian; Saeed Sohrabpour; Nasrin Yazdani; Alireza Safaee; Mohammadreza Firouzifar
Journal:  Iran J Otorhinolaryngol       Date:  2017-11

Review 6.  Intratympanic corticosteroids in Ménière's disease: A mini-review.

Authors:  Mitesh Patel
Journal:  J Otol       Date:  2017-06-26

7.  Intratympanic gentamycine for Ménière's disease: is there a selective vestibulotoxic effect?

Authors:  András Molnár; Stefani Maihoub; Anita Gáborján; László Tamás; Ágnes Szirmai
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-30       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.